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of the endocardium without the use of intrave-
nous contrast is lacking,5 the cut-off value of 50% 
for LVEF to dichotomize HFPEF from HF with re-
duced ejection fraction (HFREF) is somewhat ar-
bitrary. Maybe the simultaneous use of 2 meth-
ods, namely, echocardiography, which is more 
precise for LV diastolic dysfunction assessment, 
and cardiac magnetic resonance (CMR), which is 
better for systolic dysfunction evaluation, is the 
optimal solution, as proposed by Leong et al.6 
What is established for now, the characterization 
of HF patients should be as wide as possible, in-
cluding (except for certain clinical examinations) 
additional tests described by Brzyżkiewicz et al1 
such as echocardiography, chest X-ray, and labo-
ratory tests with special attention to HF-specif-
ic natriuretic peptides. A wide spectrum of diag-
nostic tests not only dedicated to HF is especial-
ly important in patients with HFPEF, where dif-
ferential diagnosis is pivotal.
The above considerations lead to a conclusion 
that diagnosis and, in consequence, the real prev-
alence of HFPEF are not so easy to establish. The 
estimate indicates that the prevalence of HFPEF 
among patients with HF might be about 54%, 
ranging from 40% to 71%,7 which is in agree-
ment with the results of one of the largest trials, 
the Copenhagen Hospital Heart Failure Study, in 
which the prevalence of HFPEF was 61%.8 Data 
from the National Health and Nutrition Exam-
ination Survey (NHANES) suggest an increase 
of 46% in the prevalence of HFPEF by 2030.9 In 
clinical practice, an echocardiographic examina-
tion is crucial for the determination of the fourth 
condition in HFPEF, namely, “relevant structural 
heart disease (LV hypertrophy/left atrial enlarge-
ment) and/or diastolic dysfunction”.2 
The recommendations of American and Eu-
ropean echocardiography societies10 as well as 
the ESC guidelines for the diagnosis and treat-
ment of acute and chronic HF2 agree that a good 
definition of LV diastolic dysfunction needs to 
evaluate more than 1 group of indices. The echo-
cardiographic techniques to assess LV systolic 
and diastolic function have evolved rapidly over 
the past years. New techniques of tissue Doppler 
Diastolic heart failure is a disorder character-
ized by impaired left ventricular (LV) relaxation 
and increased LV stiffness. Heart failure with pre-
served ejection fraction (HFPEF) accounts for 
40% to 50% of all HF cases and has a prognosis 
that is as dangerous as that of systolic HF.1,2 Now-
adays, HF is growing into a major health problem, 
so that recent HF guidelines have placed special 
emphasis on the detection of LV systolic and dia-
stolic dysfunction and the timely identification of 
risk factors for HF.1 Therefore, the issue addressed 
in the article of Brzyżkiewicz et al1 is particular-
ly important. The authors aimed to evaluate the 
prevalence of HF diagnosis in hypertensive pa-
tients with the first stage of diastolic dysfunction, 
namely, impaired relaxation. They based the di-
agnosis of HFPEF on the 2012 European Society 
of Cardiology (ESC) guidelines,2 which require 4 
conditions to be fulfilled: 1) typical symptoms of 
HF; 2) typical signs of HF; 3) normal or only mild-
ly reduced LV ejection fraction (LVEF) without LV 
dilation; and 4) relevant structural heart disease 
(LV hypertrophy/left atrial enlargement) and/or 
diastolic dysfunction.2 This definition seems to be 
relatively precise; however, each of the listed con-
ditions requires special attention.
The experienced clinicians are aware that “typ-
ical symptoms of HF” are not so obvious and may 
be considered as specific for HF only as a symptom 
complex, supported by the results of additional 
tests. Most of the HF symptoms taken separate-
ly are nondiscriminating and of limited diagnos-
tic value.3,4 Typical signs of HF may not be pres-
ent in the early stages of HF and may be masked 
by using diuretics in the therapy. There are nu-
merous trials that used different cut-off points 
for the diagnosis of the third condition, that is, 
normal or only mildly reduced LVEF. However, 
the majority of investigators agree that LVEF 
exceeding 50% is “normal” and LVEF below 30% 
to 35% is “reduced”. The question remains as to 
how to classify patients with LVEF between 35% 
and 50% (the so called grey area). Given the fact 
that in more than 30% of patients in a 2-dimen-
sional echocardiographic examination (common-
ly used for LVEF assessment), the clear definition 
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abnormalities are the consequence of hemody-
namic abnormalities, while in diabetes—rather 
of metabolic disturbances.15 The cumulative de-
teriorating effect of those 2 conditions was well 
documented in the study by Brzyżkiewicz et al.1 A 
relatively high prevalence (42%) of HFPEF among 
patients with isolated LV relaxation abnormalities 
(early and mild phase of diastolic dysfunction) in 
this study should not be surprising because all pa-
tients were hypertensive, more than half of them 
were diabetic, female, and rather old than young, 
judging from the mean age of 59 years.
Age, female sex, arterial hypertension, diabe-
tes, atrial fibrillation, and LV structural abnor-
malities are the well-documented risk factors for 
HFPEF.2 The results of the discussed study are in 
agreement with previously reported data, which 
emphasized the importance of hypertension, di-
abetes, age, kidney disease, and LV functional ab-
normalities as predictors of HFPEF. In a recently 
published exploratory study of patients enrolled 
in the Irbesartan in Heart Failure with Preserved 
Ejection Fraction Study (I-PRESERVE), a statis-
tical approach was used to identify HFPEF sub-
groups and validated using the Candesartan in 
Heart failure: Assessment of Reduction in Mor-
tality and morbidity (CHARM)-Preserved study, 
which may potentially differ in prognosis.16 Clin-
ical profiles and prognosis of the 6 predefined 
subgroups were similar in the CHARM-Preserved 
study. The 2 subgroups with the worst event-free 
survival in both studies were characterized by a 
high prevalence of obesity, hyperlipidemia, diabe-
tes mellitus, anemia, or renal insufficiency and by 
female predominance, advanced age, lower body 
mass index, high rates of atrial fibrillation, val-
vular disease, renal insufficiency, or anemia, re-
spectively.16 These data, together with the find-
ings of Brzyżkiewicz et al,2 highlight the need for 
active searching for the signs and symptoms of 
HF in patients with certain clinical characteris-
tics and confirmation in further laboratory tests 
and imaging evaluation. The diagnosis of HFPEF 
provides information on poor prognosis; howev-
er, no treatment has yet been shown to convinc-
ingly reduce morbidity and mortality in patients 
with diastolic HF.2,16 That it is why, an adequate 
treatment of hypertension and myocardial isch-
emia is considered to be important, as is control 
of the ventricular rate in patients with atrial fi-
brillation.2 The neccessity of proper treatment of 
obesity, diabetes, and hyperlipidemia should be 
also kept in mind.
In conclusion, the study by Brzyżkiewicz et al1 
suggests that the “known unknowns” of HFPEF 
should be more widely explored to appropriate-
ly evaluate its prevalence and prognosis and to 
facilitate the development of a life-protecting 
treatment.
imaging (TDI) enable the measurement of myo-
cardial velocities and provide valuable informa-
tion about LV diastolic function in addition to 
classical echocardiography and pulsed-wave Dop-
pler ultrasound. Currently, the absolute minimum 
is to assess the LV regional lengthening velocity 
(e’) from TDI and parameters of mitral inflow. The 
left atrial volume index (LAVI) and the above pa-
rameters are used to precisely grade LV diastolic 
dysfunction into 3 grades. Echocardiographic pa-
rameters, especially those used for assessing LV 
relaxation and filling pressure, depend not only 
on volume load but also on age, heart rate, and 
body size. The gold standard for assessing dia-
stolic function remains the pressure–volume re-
lationship, but this requires an invasive approach. 
Therefore, a comprehensive assessment of a num-
ber of echocardiographic variables is required to 
evaluate diastolic function as correctly as possi-
ble, and even so, the relationship between echo-
cardiographic and invasive hemodynamic param-
eters remains modest.11
Although not widely recommended, the new 
possibilities for the early detection of LV diastolic 
dysfunction are provided by echocardiography: di-
astolic stress testing, speckle tracking-based ear-
ly diastolic longitudinal strain rate, and speckle 
tracking-based circumferential strain measure-
ments. In this area, CMR offers the analysis of LV 
volume changes over time, which can be converted 
to filling curves as well as direct blood flow veloc-
ity measurement by velocity encoding or “phase- 
-contrast” CMR. Using gated CMR, transmitral 
and pulmonary vein flow can be measured sim-
ilarly to echocardiographic Doppler values. The 
most recent, not yet validated, ability of the CMR 
technique is the measurement of tissue veloci-
ty (LV walls).12
The study group in the discussed paper consist-
ed mainly of patients with arterial hypertension 
and diabetes mellitus who seem to be the most 
relevant choice for identifying LV diastolic dys-
function especially in early phase, that is, isolated 
abnormalities of LV relaxation. The recent 2013 
European Society of Hypertension / ESC guide-
lines for the management of arterial hypertension 
include only LV hypertrophy to the organ dam-
age signs influencing prognosis in hypertensive 
subjects. Nevertheless, the guidelines underscore 
that the most typical hypertension-induced dia-
stolic dysfunction is associated with concentric 
geometry and can induce symptoms/signs of HF 
itself, even when LVEF is still normal.13 Thus, the 
guidelines recommended the measurement of 3 
echocardiographic diastolic dysfunction parame-
ters: LAVI, septal and lateral e’ velocity, and E/e’-
-filling pressure index. The prognostic value of all 
these indices has been recognized in hyperten-
sive subjects. An increased E/e’ ratio is associated 
with increased cardiovascular risk independently 
of LV hypertrophy.14 The LAVI exceeding the cut-
off point of 34 ml/m2 is an independent predictor 
of atrial fibrillation, ischemic stroke, and fatal car-
diovascular events. In hypertension, LV relaxation 
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